XRTXF - XORTX Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1097
0.0000 (0.00%)
As of 12:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1097
Open0.1248
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1097 - 0.1097
52 Week Range0.0918 - 0.1917
Volume10,600
Avg. Volume321
Market Cap4.969M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day

    ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight in conjunction with Polycystic Kidney Disease Awareness Day, a new, eloquent research paper that describes a previously unrecognized form of injury that can occur when uric acid or calcium oxalate crystals form in the kidneys of individuals with polycystic kidney disease.  For the first time this research identifies a new pathway for accelerated cyst growth and decline of kidney function. Dr. Allen Davidoff stated, “This new research aligns closely with the therapies that XORTX is developing to slow or reverse progression of autosomal dominant polycystic kidney disease (ADPKD) in individuals with progressing kidney disease.

  • CNW Group

    OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing

    OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing

  • PR Newswire

    Live OTCQB Venture Company Investor Conference August 1st

    Company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 30, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for ...

  • PR Newswire

    XORTX Announces Virtual Investor Conference Live Webcast

    CALGARY, Alberta , July 30, 2019 /PRNewswire/ --   XORTX Therapeutics Inc. (" XORTX " or the " Company ") (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on ...

  • GlobeNewswire

    XORTX Reports Annual & Special Meeting Results

    CALGARY, Alberta, July 18, 2019 -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing.

  • GlobeNewswire

    XORTX Shares Nature Nephrology Review

    CALGARY, Alberta, July 15, 2019 -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing.

  • GlobeNewswire

    XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

    OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial statements and related management’s discussion and analysis for the year ended December 31, 2018. Both of XORTX’s advanced clinical programs are focused on treating progressive kidney disease through the lowering of serum uric acid as highlighted below in this press release.

  • GlobeNewswire

    XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression

    OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, congratulates the TODAY study team and Dr. Petter Bjornstad on successful completion of their study and findings in youths with Type 2 Diabetes (“T2D”).  The findings show for the first time that high uric acid levels are common in young patients with T2D nephropathy (“T2DN”) and that high serum uric acid levels (“SUA”) are an independent risk factor for progression of kidney disease in this newly described and vulnerable group. In addition, the effects of SUA as an independent risk factor on high blood pressure and protein excretion (albuminuria/ proteinuria) into the urine are also described1.

  • GlobeNewswire

    XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor

    CALGARY, Alberta, March 25, 2019 -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative.

  • GlobeNewswire

    XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited

    CALGARY, Alberta, March 12, 2019 -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative.

  • GlobeNewswire

    XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference

    CALGARY, Alberta, Jan. 28, 2019 -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative.